Clinical implications and novel therapies

P. Barnes (London, United Kingdom)

Source: International Congress 2018 – Accelerated ageing in lungs
Session: Accelerated ageing in lungs
Session type: Symposium
Number: 3552

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Barnes (London, United Kingdom). Clinical implications and novel therapies. International Congress 2018 – Accelerated ageing in lungs

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008


Clinical implications
Source: Annual Congress 2007 - Pulmonary biomarkers in COPD
Year: 2007


Therapeutic implications
Source: Annual Congress 2009 - The lung cancer-COPD nexus
Year: 2009


COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007


Clinical implications of the new concepts regarding COPD pathophysiology
Source: Annual Congress 2008 - New insights into COPD pathophysiology
Year: 2008


Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020
Year: 2020



Clinical implications – potential future developments in EBC research
Source: Annual Congress 2007 - ERS/ATS joint symposium: the report of the ERS/ATS Task Force on Exhaled Breath Condensate
Year: 2007


COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020



Novel targets and emerging therapies in MPM
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019

Potential of regulatory T-cell-based therapies in the management of severe COVID-19
Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020
Year: 2020



Therapeutic management - Current status and future developments
Source: COVID-19 Videos
Year: 2020

Recommendations of new therapies for severe asthma and the future
Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma
Year: 2013


Physiologic rationale and clinical pitfalls
Source: Virtual Congress 2021 – High flow nasal cannula in adults with acute respiratory failure
Year: 2021


Therapeutic and management implications
Source: Annual Congress 2010 - Similarities and differences between asthma and COPD: the "Dutch Hypothesis" revisited
Year: 2010


Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers
Source: Eur Respir J, 55 (5) 2001028; 10.1183/13993003.01028-2020
Year: 2020



Evidence-based medicines for children: important implications for new therapies at all ages
Source: Eur Respir J 2006; 28: 1069-1072
Year: 2006